Data Integrity, Lab Control Issues Lead to 483s for Two Manufacturers Post author:Sam Post published:February 12, 2017 Post category:Drug GMP Report The FDA issued Form 483s to two drug manufacturers for data integrity and laboratory issues. Source: Drug GMP Report You Might Also Like Strides Gets 483 for Quality Problems July 3, 2017 FDA Gives (Gentle) Nudge to Industry on Stem Cells July 9, 2019 EMA’s PRAC Recommends New Safety Warnings, Side-Effect Labeling November 13, 2017